Suraksha Diagnostic Limited — PPTs, 10-11-2025: Investor Presentation

Suraksha Diagnostic reported strong H1 FY26 financials with total income up 18% YoY to ₹153.1 Cr, driven by expanding operations. Q2 income rose 17% YoY to ₹79.6 Cr. While EBITDA for H1 grew 7% to ₹49.6 Cr (margin 32.8%) and for Q2 rose 2% to ₹25.0 Cr (margin 31.7%), new centre additions impacted overall profitability. Q2 PAT was ₹8.8 Cr (-13% YoY) and H1 PAT was ₹18.0 Cr (+1% YoY). H1 EPS stood at ₹3.53.

The company is in expansion mode, adding 5 new centres in Q2, bringing its total to 63. A strategic highlight was the launch of 'Suraksha Genomics' in July, tapping into high-growth genetic and molecular testing. Suraksha also acquired a 63% stake in Fetomat Wellness, integrating fetal medicine expertise.

Management noted that mature centres achieve 37-38% EBITDA margins, but the 21 newer centres (15 less than a year old) currently weigh on overall margins. They anticipate margins will normalize as these new centres mature and scale up, emphasizing prudent expansion and continued focus on enhancing their one-stop diagnostic model and technology investments.